We report on two sessions on atrial fibrillation, two on heart failure, two on hypertension, and one each on endocarditis and ST-elevation myocardial infarction.
We report on two sessions on atrial fibrillation, two on heart failure, two on hypertension, and one each on endocarditis and ST-elevation myocardial infarction.
Cablivi (caplacizumab-yhdp) for acquired thrombotic thrombocytopenic purpura; Egaten (triclabendazole) for fascioliasis; and Spravato (esketamine) for treatment-resistant depression.
This in-depth article on the sixth leading cause of death in the U.S. reports on the optimism of cutting-edge leaders in Alzheimer's disease research. The author examines key considerations such as the status of biomarker tests, and the search for new biomarkers; securing an accurate definition of the disease; risk factors; clinical trials and non-pharmacological studies.
Increased cannabis use has brought about a sea change in policy and attitudes toward regulation, and a multitude of rules that vary widely between states. The disparity has stymied any effective response to the problems surrounding access to cannabis products for those in need. Health care providers and practitioners, as well as P&T committees, must carefully undertake decisions on rational drug use, whether or not their patients are using cannabis while under their care.
Indication-based prescribing has many potential benefits, including preventing errors by reducing medication choices and assisting with medication reconciliation.
Cannabidiol oral solution for seizures associated with Lennox-Gastaut and Dravet syndromes.
What lies behind the growth of rising hospital prices? Many factors-including the impact of hospital mergers and the industry's complicated relationship with Congress.
Approvals, new indications and formulations, and safety issues.
Virtual reality (VR) has been widely studied and applied in numerous medical applications.1 In pharmacy, VR can potentially be applied as follows: adjunctively or as a replacement for pharmacotherapy; in drug design and discovery; in pharmacist education; and in patient counseling and behavior modification.1-6 Research applying VR in pharmacy is currently limited; however, interest in these applications is increasing. The majority of studies conducted during the past decade have found VR to be safe and effective, and to promote a high degree of user satisfaction.4 VR technology has become increasingly affordable, flexible, and portable, enabling its use for therapeutic purposes in both inpatient and outpatient environments.4 But despite the compelling features of VR, a number of challenges exist, such as validation of clinical efficacy, cost/accessibility and usability issues, technical capabilities, and acceptance.1-5 This article discusses the potential for the use of VR in pharmacy for clinical, research, and educational applications.
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：